Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharming Group (PHAR)
NASDAQ:PHAR
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.02Last Year’s EPS
-0.04Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 25, 2018
|% Change Since: -1.00%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in RUCONEST and Joenja sales, along with strategic developments such as the new Phase II trial. However, the company faced a net loss due to increased operating expenses and financial challenges. Overall, the positive revenue trends and strategic progress were balanced by financial challenges, indicating a mixed outlook.Company Guidance
During the Q3 2024 earnings call for PHARM.AS, the company provided guidance highlighting significant financial and operational metrics. RUCONEST continues as a cornerstone, generating over $64 million in Q3 and nearly $173 million for the first nine months of 2023, marking a 12% growth year-to-date. The company also reported Joenja's impressive revenue of $32 million in the same period, driven by its introduction as the sole FDA-approved treatment for APDS, a rare immune disorder. The firm is expanding Joenja's market presence beyond the U.S., U.K., and Israel, with plans to pursue pediatric label expansion and entry into additional markets like Japan and Australia. Financially, the company achieved a gross profit increase of $35.3 million year-to-date, in line with revenue growth, and maintains a cash position of $173.3 million. Despite a net loss of $14.7 million for the first nine months, PHARM.AS remains optimistic about reaching the midpoint of its revenue guidance of $82 million to $95 million for the full year, supported by continued growth in patient numbers and strategic expansion efforts.RUCONEST Revenue Growth
RUCONEST continues to perform well in the hereditary angioedema market, with a 12% revenue growth year-to-date, reaching $172.6 million.
Joenja Sales Increase
Joenja, the treatment for APDS, achieved $32 million in sales year-to-date, with a growth of 210% compared to the first nine months of last year.
Phase II Trial Initiation
The company started a Phase II trial for leniolisib in primary immune deficiencies, a significantly larger market than APDS.
Increased Cash Flow
Cash and cash equivalents increased to $173.3 million, driven by positive cash flows from operations of $9.7 million.
Strong Patient Enrollment
RUCONEST saw over 100 new patient enrollments in Q3, with a prescriber base increase towards 800 total.
---
PHAR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHAR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 24, 2024 | $8.96 | $8.30 | -7.37% |
| Aug 01, 2024 | $8.33 | $7.63 | -8.40% |
| May 08, 2024 | $9.66 | $9.50 | -1.66% |
| Mar 14, 2024 | $11.11 | $10.92 | -1.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pharming Group (PHAR) report earnings?
Pharming Group (PHAR) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Pharming Group (PHAR) earnings time?
Pharming Group (PHAR) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAR EPS forecast?
PHAR EPS forecast for the fiscal quarter 2024 (Q4) is 0.02.
---